Laurus Labs Limited

rs,

anuary 24, 2025 To To The Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 The Listing Department National Stock Exchange of India Ltd., Ex

₹ 3,834

iver Full Year growth with further Q4 revenues acceleration driven by planned project deliveries; ₹ 3,834 Cr Revenues in 9M and 6% revenues growth Strengthening operational performance in CMO/CDMO with co

6%

rther Q4 revenues acceleration driven by planned project deliveries; ₹ 3,834 Cr Revenues in 9M and 6% revenues growth Strengthening operational performance in CMO/CDMO with continued demand for compl

₹ 638

ngthening operational performance in CMO/CDMO with continued demand for complex API capabilities ₹ 638 Cr EBITDA resulted in a margin of 16.6%, improved steadily with the gradual step-up in the asset ut

16.6%

/CDMO with continued demand for complex API capabilities ₹ 638 Cr EBITDA resulted in a margin of 16.6%, improved steadily with the gradual step-up in the asset utilization • Gross margins remained st

55.8%

ed steadily with the gradual step-up in the asset utilization • Gross margins remained strong at 55.8% on positive product mix • • Improved S&P DJSI ESG Score to 71* (+12 pts over LY) and Investmen

₹ 120

ails Subsidiary Laurus Bio signed definitive agreement on 6 Dec’24, to raise equity investment of ₹ 120 Cr from Eight Roads Ventures and F-Prime Capital. In addition, Laurus Labs has also agreed to co-in

₹ 40

Ventures and F-Prime Capital. In addition, Laurus Labs has also agreed to co-invest an additional ₹ 40 Cr at the same valuation. Upon completion of the transaction, Company and Eight Roads will hold 75%

75%

40 Cr at the same valuation. Upon completion of the transaction, Company and Eight Roads will hold 75% and 14% stake in Laurus Bio. Laurus Labs or Eight Roads have the right to invest up to an addition

14%

the same valuation. Upon completion of the transaction, Company and Eight Roads will hold 75% and 14% stake in Laurus Bio. Laurus Labs or Eight Roads have the right to invest up to an additional amoun

₹ 35

e in Laurus Bio. Laurus Labs or Eight Roads have the right to invest up to an additional amount of ₹ 35 Cr before Dec 2025 Rationale • • • • Eight Roads Ventures and Laurus Labs financial collaborat

80%

by end of 2026 Pic © 2024 Laurus Labs Ltd. Q3 & 9M - FY25 Results Presentation 24/01/2025 6 +80% CAPEX invested to support growth; execution ramping up - Targeting Average asset turnover levels

“Expect growth returning next year with positive order bookings convert to sales Formulation (FDF): Continued volume led growth (+33% Q/Q) across ARV and Developed mkt sales.”

“CMO opportunities building up and new launches expect to further support growth in coming quarters”

“Q3 & 9M - FY25 Results Presentation 24/01/2025 14 LAURUSLabs Chemistry for Better Living 28%3%31%38%CDMOBioFDFAPIs Business Performance 9M/FY25 - 9M/FY25 Divisional Revenue Performance [₹ Crore] 9M/FY25 9M/FY25 Y-o-Y CDMO-Synthesis APIs FDF Bio Total Revenues 913 1,752 1,038 131 3,834 9M/FY25 Revenue Mix 33% -3% 5% 0% 6% 686 1,800 984 131 3,601 ■ ■ ■ ■”

“Committed to 2025 growth outlook, supported by scheduled project deliveries in Q4.”

“CMO engagement continued with segment returning to growth next year Formulation (FDF): 9M returns to growth +5%, with strong Q/Q progression across ARV (+40%) and Developed market portfolio sales (+20%); orders book healthy.”

“New launches expect to further support growth”

“New R&D facility equipped with advanced capability (flow chemistry, biocatalysis, and HP API) meets strong interest from new/existing Big pharma clients Planned capacity expansion on track; Dedicated new DS block at Unit-4, Animal health DS facility (LSLP-U2) MB-4 u/construction phase, Crop protection facility2 qualification targeted by end of FY25 2 Multi year Development and manufacturing contract already signed © 2024 Laurus Labs Ltd.”

“Q3 & 9M - FY25 Results Presentation 24/01/2025 16 LAURUSLabs Chemistry for Better Living 6869132122362142994009MFY249MFY253QFY244QFY241QFY252QFY253QFY25 CDMO – Other key updates - • • Small molecules CDMO pipeline healthy; Working on +70 active projects including several breakthrough designated molecules (10 commercial incl.”

“2nd facility going on-stream in mid-2025 Gene therapy Precision fermentation • • India’s 1st Gene GMP facility build on track - Phase 1 coming online during Q2 FY26 Capability to do plasmids DNA and vectors of various types i.e.”

“LV, AAV • More partners exploring greener and lower cost enzyme catalytic synthesis routes • Over 10+ active Bio catalysis project • Microbial fermentation site (cGMP grade) build on track 1 Indication for relapsed refractory r/r Multiple Myeloma, * Granted commercial authorization by CDSCO (Indian regulatory agency) in Oct 2023 for r/r B-cell malignancies © 2024 Laurus Labs Ltd.”

CDMO

2

APIs

2

Bio

2

CDMO

Up +89% on new assets ramp-up and advancing clinical projects further accelerating growth. New R&D facility with advanced capability meets strong market interest while RFP pace continuing momentum. Capacity expansion on track

APIs

Down by 7% due to capacity constrain in ARV however, remain committed to full year contractual deliveries. Positive order intake and cost efficiency continued. Expect growth returning next year with positive order bookings convert to sales Formulation (FDF): Continued volume led growth (+33% Q/Q) across ARV and Developed mkt sales. CMO opportunities building up and new launches expect to further support growth in coming quarters

Bio

AOF/CDMO driving healthy underlying growth. Expanding high- throughput systems to meet increasing demand. Eight Roads alliance further transforming bio-capability at scale © 2024 Laurus Labs Ltd. Q3 & 9M - FY25 Results Presentation 24/01/2025 14 LAURUSLabs Chemistry for Better Living 28%3%31%38%CDMOBioFDFAPIs Business Performance 9M/FY25 - 9M/FY25 Divisional Revenue Performance [₹ Crore] 9M/FY25 9M/FY25 Y-o-Y CDMO-Synthesis APIs FDF Bio Total Revenues 913 1,752 1,038 131 3,834 9M/FY25 Revenue Mix 33% -3% 5% 0% 6% 686 1,800 984 131 3,601 ■ ■ ■ ■

CDMO

Up +33% driven by continued uptake with new assets ramping up and execution on clinical pipeline. Committed to 2025 growth outlook, supported by scheduled project deliveries in Q4. Enhancing platform advantage with RFP pace continuing momentum.

APIs

Soft, due to prioritized ARV capacity reallocation towards high yielding long-term business opportunities. ARV order book healthy and remain committed to fulfil contractual obligations. CMO engagement continued with segment returning to growth next year Formulation (FDF): 9M returns to growth +5%, with strong Q/Q progression across ARV (+40%) and Developed market portfolio sales (+20%); orders book healthy. New launches expect to further support growth

Bio

Healthy underlying 9M performance and increased customer pipeline building activity across AOF/CDMO. Positive market demand for Bio- offering continuing and further expanding R&D capacity. © 2024 Laurus Labs Ltd. Q3 & 9M - FY25 Results Presentation 24/01/2025 15 LAURUSLabs Chemistry for Better Living 24%3%27%46%CDMOBioFDFAPIs CDMO – Enhancing platform advantage; Growth outlook intact - [₹ Cr] +33% r Revenue Growth Comments Y-o-Y ▲ 89% Q-o-Q ▲ 34% • • Sustained demand for difficult-to-make small molecules 9M growth reflects continued uptake with new assets ramping up and execution on clinical pipeline • Committed to 2025 healthy growth outlook, supported by scheduled project deliveries in Q4 • • Encouraging RFPs and signing in early-mid-late phase projects involving complex chemistry. New R&D facility equipped with advanced capability (flow chemistry, biocatalysis, and HP API) meets strong interest from new/existing Big pharma clients Planned capacity expansion on track; Dedicated new D